Clinical Trial Update: A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 clinical study evaluating recombinant human coagulation factor VIII for injection in severe hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Recombinant human coagulation factor VIII for injection (recombinant human coagulation factor VIII)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Hemophilia A | Phase 3 | Status: UNKNOWN